What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

The POC testing market is set to reach $49 billion by 2018.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

The POC testing market is set to reach $49 billion by 2018.

The StiffnoGraph belongs to the group of finger pulse oximeters and is used on adults and children by healthcare professionals, such as general practitioners, ortho-molecular practitioners, sports physicians, naturopaths, alternative medicine practitioners, dieticians and physiotherapists. The StiffnoGraph is a non-invasive, fingertip device used in health care to estimate arterial stiffening, SpO2 and heart rate and to evaluate the vitamin K status (in combination with Vermeer Index). This revolutionary device enables healthcare providers to quickly estimate the vasclar characteristics and thus to estimate the risk of vitamin K insufficiency. Insufficient intake of this vitamin, but also of the vitamines B12, C, D or E is a risk factor for a number of diseases.

Principles of measurement:
Vascular characteristics are recorded by a technique known as accelerated plethysmography, which was specifically adapted for the applications set out below. The device contains a dual light source (red LED and infrared LED) and a photodetector. Bone, tissue, pigmentation, and venous blood absorb a constant amount of light over time. The arteriolar blood, however, pulsates and absorbs variable amounts of light during the pulsations of the blood flow. The underlying technology enables the StiffnoGraph to measure and display reliable values for SpO2, heart rate and vascular stiffness. In combination with the Vermeer index, the StiffnoGraph can be used to evaluate the risk of vascular vitamin K insufficiency.
( For more information please visit our Knowledge-Center on this website: http://www.vitak.com/knowledge-center/ )

Warning:

  • The classification of artery condition and blood circulation condition is for reference purposes only. Please consult a physician for further advice.
  • The StiffnoGraph is intended only as an aid in patient assessment. It must be used in conjunction with other diagnostic methods.
  • The StiffnoGraph should only be used by health professionals such as general practitioners, orthomolecular practitioners, sports physicians, naturopaths, alternative medicine practitioners, dieticians and physiotherapists.
  • Arterial stiffness is classified into 6 levels, for a correct interpretation of the images the client’s age should also be taken into consideration. Please be aware that this is only a symbolic representation of vascular stiffening.
  • Inform your client about the purpose and implementation of the measurement.
  • The finger should be clean. Nail polish or gel/acrylic fingernails should be removed because they can give false results or an error sign on the display.
  • When the fingers are cold, the blood flow is reduced; this can lead to poor or abnormal readings. Warming the hands by rubbing, or washing with warm water helps to improve the blood flow.
  • The battery may leak or explode if used or disposed improperly. Remove the battery if the device will be stored unused for more than 30 days.
  • The StiffnoGraph should be operated by trained personnel only.
  • Don’t use the StiffnoGraph in an MRI or CT environment, in an explosive atmosphere, or on infants or neonates.
  • The StiffnoGraph is intended only as an aid in patient assessment. It must be used in conjunction with other diagnostic methods.
  • Remove any objects that may hinder the performance of the StiffnoGraph (for example blood pressure cuffs).
  • Keep the StiffnoGraph away from young children. Small items such as the battery cover and battery may form choking hazards.
  • Significant levels of dysfunctional hemoglobin, such as carboxyhemoglobin or methemoglobin, may affect the accuracy of the measurement.
  • Intravascular dyes, such as Cardiogreen, may affect the accuracy of the StiffnoGraph.
  • The performance of the StiffnoGraph may be affected by the presence of a defibrillator.
  • Client/patient should be calm during the measurement and the hand should be in a stable position. The accuracy of the StiffnoGraph may be compromised if the measurement is performed immediately after exercising or after shaking hands.
  • Don’t use the StiffnoGraph in combination with an infusion in the arm, this may interfere with the blood flow and cause inaccurate measurements.
  • The operation of the StiffnoGraph may be affected by the use of an electrosurgical unit (ESU).
  • The StiffnoGraph should not be used adjacent to or simultaneous with other equipment. If adjacent or simultaneous use is necessary, the device should be observed carefully to verify normal operation.
  • Use of the lanyard can pose a risk of injury, such as strangulation.
  • The StiffnoGraph display will go blank after 15 seconds of disuse.
  • Do not sterilize, autoclave, or immerse the StiffnoGraph in liquid. Do not pour or spray any liquids onto the device.
  • Do not use caustic or abrasive cleaning agents, or any cleaning agent containing ammonium chloride or isopropyl alcohol.
  • A flexible circuit connects the two halves. Do not twist or pull the flexible circuit or overextend the device’s spring.
  • The StiffnoGraph complies with IEC 60601-1-2 for electromagnetic compatibility for medical electrical equipment and/ or systems. This standard is designed to provide reasonable protection against harmful interference in a typical medical environment. However, because of the increasing use of radiofrequency transmitting equipment and other sources of electrical noise in healthcare and other environments, it is possible that high levels of such interference, or close proximity or strength thereof, may affect the performance of the StiffnoGraph.
  • Portable and mobile wavelength emitting communication equipment may affect medical electrical equipment.
  • Follow local, state, and national directives and recycling instructions regarding disposal or recycling of the StiffnoGraph and components, including the battery.
  • Do not open the StiffnoGraph except for the battery cover. The StiffnoGraph contains no user-serviceable parts. Only qualified service personnel should perform maintenance services.
  • Do not expose the StiffnoGraph to moisture, so that accurate performance and device safety can be ensured.
  • In compliance with the European Directive on Waste Electrical and Electronic Equipment (WEEE), do not dispose the StiffnoGraph as unsorted municipal waste. The StiffnoGraph contains WEEE materials; please contact your distributor for take-back or recycling of the device.
  • Follow the general guidelines for point of care testing when using the StiffnoGraph.

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com